9 Meters Biopharma (NMTR) Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NMTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NMTR, but not buy additional shares or sell existing shares.
View NMTR analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 12-month price targets for 9 Meters Biopharma's shares. Their NMTR share price forecasts range from $1.70 to $100.00. On average, they predict the company's stock price to reach $44.18 in the next twelve months. This suggests a possible upside of 5,790.0% from the stock's current price.
View analysts price targets for NMTR or view top-rated stocks among Wall Street analysts.

9 Meters Biopharma's stock was trading at $1.26 at the beginning of 2023. Since then, NMTR stock has decreased by 40.5% and is now trading at $0.75.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our NMTR earnings forecast.

9 Meters Biopharma, Inc. (NASDAQ:NMTR) released its quarterly earnings results on Monday, November, 15th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.26.

9 Meters Biopharma's stock reverse split on Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other 9 Meters Biopharma investors own include Acasti Pharma (ACST), Miragen Therapeutics (MGEN), Bionano Genomics (BNGO), Evofem Biosciences (EVFM), Outlook Therapeutics (OTLK), Tonix Pharmaceuticals (TNXP), Alibaba Group (BABA), Cellectar Biosciences (CLRB), Pfizer (PFE) and Soleno Therapeutics (SLNO).

9 Meters Biopharma trades on the NASDAQ under the ticker symbol "NMTR."

9 Meters Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Sabby Management LLC (7.70%), CIBC Asset Management Inc (0.23%), Susquehanna International Group LLP (0.00%) and HRT Financial LP (0.13%). Insiders that own company stock include Bethany Sensenig, Edward J Sitar, Israel Gp Ltd Orbimed, John Temperato, Mark A Sirgo and Michael T Constantino.
View institutional ownership trends.

Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NMTR stock can currently be purchased for approximately $0.75.

9 Meters Biopharma (NASDAQ:NMTR) has a market capitalization of $10.76 million. The company earns $-43,770,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis.

9 Meters Biopharma's mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The official website for the company is www.9meters.com. The company can be reached via phone at (919) 275-1933 or via email at investor-relations@9meters.com.